Related Experiment Video
Updated: Jun 9, 2025
A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
Kidney Cancer Research Highlights from ASCO-GU 2024 Meeting
Yasser Ged1, Nirmish Singla1,2
1Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Abstract:
The 2024 American Society of Clinical Oncology (GU ASCO 2024) Genitourinary Cancers Symposium brought together leading cancer specialists from around the world to discuss the latest breakthroughs in treating genitourinary cancers, especially kidney cancer. The focus was on immunotherapy and combination treatments, offering promising new options for patients with advanced and high-risk tumors. The symposium also highlighted advancements in patient care, including a new tool to assess quality of life in people with metastatic kidney cancer.
Insights
The 2024 Genitourinary Cancers Symposium highlighted advancements in kidney cancer treatment, focusing on immunotherapy and combination therapies for advanced tumors. New tools also emerged to improve quality of life assessments for patients with metastatic kidney cancer.
Area of Science:
- Oncology
- Genitourinary Cancers
- Medical Symposia
Background:
- The 2024 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium convened global experts.
- Discussions centered on cutting-edge treatments for genitourinary malignancies, with a particular emphasis on kidney cancer.
Purpose of the Study:
- To summarize key findings and treatment trends presented at GU ASCO 2024.
- To highlight advancements in immunotherapy and combination therapies for genitourinary cancers.
- To report on innovations in patient care and quality of life assessment tools.
Main Methods:
- Review of presentations and discussions from the GU ASCO 2024 symposium.
- Focus on research related to kidney cancer, immunotherapy, and combination treatment strategies.
- Identification of novel tools for assessing patient quality of life.
Main Results:
- Immunotherapy and combination treatments show significant promise for advanced and high-risk genitourinary tumors, especially kidney cancer.
- New therapeutic strategies are emerging, offering potential for improved patient outcomes.
- A novel tool for assessing quality of life in patients with metastatic kidney cancer was introduced.
Conclusions:
- The GU ASCO 2024 symposium underscored the rapid progress in genitourinary cancer treatment.
- Immunotherapy and combination approaches represent a major frontier in managing advanced kidney cancer.
- Enhancements in patient-reported outcome measures are crucial for comprehensive care in metastatic kidney cancer.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...